Chadi Nabhan, MD, MBA, FACP, Discusses Highlights from The HemOnc Pulse at ASCO
By Chadi Nabhan, MD, MBA, FACP, Leah Sherwood - Last Updated: June 14, 2023Chadi Nabhan, MD, MBA, FACP, host of The HemOnc Pulse, discusses key highlights from The HemOnc Pulse during the 2023 American Society of Clinical Oncology Annual Meeting.
Advertisement
Dr. Nabhan shares his experience hosting the podcast, as well as what he hopes listeners gain from it.
The HemOnc Pulse, which covers all topics in the world of hematologic oncology, is brought to you by Blood Cancers Today and the Society of Hematologic Oncology.
Find all episodes of The HemOnc Pulse here.
Post Tags:ASCO2023
Advertisement
Related Posts
Non-Hispanic Black women had the highest odds for hypertensive disorders of pregnancy, preterm birth, and fetal death.
Phase 1b data suggest that continuous low-dose lenalidomide improves the therapeutic index in patients RRMM.
ISB 2001, a novel BCMA-targeting trispecific antibody, showed increased expression of T-cell activation cell surface markers.
A QSP model of ISB 2001, a novel trispecific antibody, offers an effective pathway for designing phase 1 studies.
Efficacy and safety profile data were presented at the AACR Annual Meeting 2025.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.